Who is sponsoring NCT04969653?

NCT04969653 is sponsored by Momentum Data.

What drugs are being tested in NCT04969653?

Interventions in NCT04969653: Exposure of venous thromboembolism.

What condition does NCT04969653 study?

NCT04969653 studies Venous Thromboembolism, Atopic Dermatitis, Pulmonary Embolism, Deep Vein Thrombosis, Allergic Rhinitis, Allergy to House Dust Mite, Allergy to Animal Dander, Food Allergy, Cows Milk Allergy.

Is NCT04969653 still recruiting?

NCT04969653 is currently completed. Last updated 9 December 2024.

Are results published for NCT04969653?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2024-12-09 · How we verify

NCT04969653

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

The Incidence of Venous Thromboembolism in Atopic Dermatitis

Completed Results posted Last updated 9 December 2024

What this trial tests

trial testing Exposure of venous thromboembolism in Venous Thromboembolism in 754,745 participants. Completed in 1 July 2023.

Timeline

21 June 2021

Primary endpoint
31 March 2023

1 July 2023

Quick facts

Lead sponsor	Momentum Data
Status	Completed
Study type	OBSERVATIONAL
Enrollment	754,745
Start date	21 June 2021
Primary completion	31 March 2023
Estimated completion	1 July 2023
Sites	1 location across United Kingdom

Drugs / interventions tested

Exposure of venous thromboembolism

Conditions studied

Venous Thromboembolism — all drugs for Venous Thromboembolism →
Atopic Dermatitis — all drugs for Atopic Dermatitis →
Pulmonary Embolism — all drugs for Pulmonary Embolism →
Deep Vein Thrombosis — all drugs for Deep Vein Thrombosis →

Sponsor

Momentum Data

Who can join

18 and older, any sex, with Venous Thromboembolism or Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Number of Participants With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person. Primary · 10 years from index date

To describe the risk of venous thromboembolism (composite of pulmonary embolism and deep vein thrombosis) in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	2576
Controls	7563

Number of Participants With Diagnosis of Pulmonary Embolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To describe the risk of pulmonary embolism in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	797
Controls	2942

Number of Participants With Diagnosis of Deep-vein Thrombosis After the Start of Follow-up for Each Person Secondary · 10 years from index date

To describe the risk of deep-vein thrombosis in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	1887
Controls	4934

Number of Male Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by the male sex at the baseline in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	1070
Controls	3170

Number of Female Participants With Diagnosis of Risk of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by the female sex at the baseline in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	1506
Controls	4393

Number of Participants Aged 18-44 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by those aged 18-44 at the baseline in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	503
Controls	1592

Number of Participants Aged 45-64 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by those aged 45-64 at the baseline in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	639
Controls	1858

Number of Participants Aged ≥65 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by those aged ≥65 at the baseline in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	1434
Controls	4113

Number of Participants BMI <30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by those with a BMI \<30 at the baseline with active AD compared to a matched control population. Patients with active AD and missing BMI are excluded along with their related matched cases. Patients with active AD and no matched controls with BMI recorded are also excluded.

Group	Value	95% CI
Cases	1398
Controls	3188

Number of Participants BMI ≥30 With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by those with a BMI ≥30 at the baseline in people with active AD compared to a matched control population. Patients with active AD and missing BMI are excluded along with their related matched cases. Patients with active AD and no matched controls with BMI recorded are also excluded.

Group	Value	95% CI
Cases	685
Controls	760

Number of Female Participants Aged 18-44 Using Oestrogen Contraceptive With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore the risk of VTE stratified by oestrogen contraceptive use in females aged 18-44 years at the baseline in people with active AD compared to a matched control population.

Group	Value	95% CI
Cases	31
Controls	34

Number of Participants Having History of an Allergic Condition With Diagnosis of Venous Thromboembolism After the Start of Follow-up for Each Person Secondary · 10 years from index date

To explore risk of VTE stratified by the presence, or absence of allergic conditions at baseline in people with active AD compared to a matched control population.. Allergic conditions will comprise common allergies; allergic rhinitis, allergy to dust mites or animal dander, and food allergies e.g., nut, fruit, shellfish, eggs and cows' milk allergies. Medication and other allergies will not be included.

Group	Value	95% CI
Cases	193
Controls	203

Sponsor's own description

This study aims to investigate the incidence of venous thromboembolism in people who are diagnosed with atopic dermatitis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Venous Thromboembolism

Currently open trials in the same condition.

NCT07399977 — Using a Blood Test and Software Tool to Guide Treatment for Venous Thromboembolism · NA · recruiting
NCT06861088 — The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer · Phase 3 · recruiting
NCT07140523 — A Study to Compare the Efficacy and Safety of SRSD107 and Enoxaparin in Adult Subjects Undergoing TKA · Phase 2 · recruiting
NCT04211181 — CHIPs-VTE Study in Hospitalized Patients to Prevent Hospital-Acquired Venous Thromboembolism · NA · recruiting
NCT06440694 — Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) · Phase 3 · recruiting

Other Momentum Data trials

Trials by the same sponsor.

NCT06097494 — Investigating Healthcare Disparities in Vitiligo · completed
NCT05727306 — Healthcare Disparities in Alopecia Areata · completed
NCT05206734 — Risk of Mental Health Conditions in Children and Young Adults With Inflammatory Bowel Disease and Influence on Health · completed
NCT04969419 — Incidence of Melanoma and Non-melanoma Skin Cancer in People With Vitiligo · completed
NCT04953338 — Mental Health Associations With Vitiligo · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04969653 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Momentum Data
Last refreshed: 9 December 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04969653.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing